Cadrenal Therapeutics Inc. (CVKD) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
822 A1A NORTH PONTE VEDRA, FL 32082 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)
| 9/30/2024 MRQ | 12/31/2023 | 12/31/2022 | |||
|---|---|---|---|---|---|
| ASSETS | |||||
| Current Assets | |||||
| Cash, cash equivalents, and short-term investments | 8,402,500 | 32,586 | |||
| Cash and cash equivalents | 8,402,500 | 32,586 | |||
| Prepaid expense | 89,673 | 22,715 | |||
| Deferred costs | 672,295 | ||||
| Total current assets: | 8,492,173 | 727,596 | |||
| Noncurrent Assets | |||||
| Operating lease, right-of-use asset | 20,998 | 43,578 | |||
| Property, plant and equipment | 2,287 | 1,013 | |||
| Other noncurrent assets | 3,792 | 5,987 | |||
| Total noncurrent assets: | 27,077 | 50,578 | |||
| TOTAL ASSETS: | 8,519,250 | 778,174 | |||
| LIABILITIES AND EQUITY | |||||
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 805,525 | 1,268,461 | |||
| Accounts payable | 167,319 | 404,897 | |||
| Accrued liabilities | 638,206 | 863,564 | |||
| Other undisclosed current liabilities | 21,350 | 66,016 | |||
| Total current liabilities: | 826,875 | 1,334,477 | |||
| Noncurrent Liabilities | |||||
| Long-term debt and lease obligation | 553,340 | ||||
| Long-term debt, excluding current maturities | 553,340 | ||||
| Liabilities, other than long-term debt | 4,441,507 | ||||
| Accrued environmental loss contingencies | 40,213 | ||||
| Operating lease, liability | 21,350 | ||||
| Derivative instruments and hedges, liabilities | 4,379,944 | ||||
| Total noncurrent liabilities: | 4,994,847 | ||||
| Total liabilities: | 826,875 | 6,329,324 | |||
| Equity | |||||
| Equity, attributable to parent | 7,692,375 | (5,551,150) | |||
| Common stock | 13,022 | 8,194 | |||
| Additional paid in capital | 22,750,768 | 1,154,985 | |||
| Accumulated deficit | (15,071,415) | (6,714,329) | |||
| Total equity: | 7,692,375 | (5,551,150) | |||
| TOTAL LIABILITIES AND EQUITY: | 8,519,250 | 778,174 | |||
Income Statement (P&L) (USD)
| 9/30/2024 TTM | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|
| Gross profit: | (220,095) | |||
| Operating expenses | (7,632,843) | (2,701,628) | ||
| Other undisclosed operating income | 220,095 | |||
| Operating loss: | (7,632,843) | (2,701,628) | ||
| Nonoperating income (expense) | (724,243) | |||
| Investment income, nonoperating | 245,558 | |||
| Interest and debt expense | (740,139) | (40,192) | ||
| Net loss: | (9,097,225) | (2,741,820) | ||
| Net income attributable to noncontrolling interest | 6,714,329 | |||
| Other undisclosed net income (loss) attributable to parent | 740,139 | (10,686,838) | ||
| Net loss available to common stockholders, diluted: | (8,357,086) | (6,714,329) | ||
Comprehensive Income (USD)
| 9/30/2024 TTM | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|
| Net loss: | (9,097,225) | (2,741,820) | ||
| Other undisclosed comprehensive loss | (3,972,509) | |||
| Comprehensive loss, net of tax, attributable to parent: | (9,097,225) | (6,714,329) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.